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Decreased Langerhans Cell Responses to IL-36γ: Altered
Innate Immunity in Patients with Recurrent Respiratory
Papillomatosis
James DeVoti,1,3* Lynda Hatam,1,3* Alexandra Lucs,1,4 Ali Afzal,2 Allan Abramson,1,4 Bettie Steinberg,2,4 and
Vincent Bonagura1,2,3
1

Feinstein Institute for Medical Research, Manhasset, New York, United States of America; 2Elmezzi Graduate School of Molecular
Medicine, Manhasset, New York, United States of America; 3Division of Allergy and Immunology, Department of Pediatrics and
4
Department of Otolaryngology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America

Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease caused by human papillomaviruses (HPVs) types 6 and 11
that is characterized by the polarization of adaptive immune responses that support persistent HPV infection. Respiratory papillomas express elevated mRNA levels of IL-36γ, a proinflammatory cytokine in comparison to autologous clinically normal laryngeal
tissues; however there is no evidence of inflammation in these lesions. Consistent with this, respiratory papillomas do not contain
TH1-like CD4+ T-cells or cytotoxic CD8+ T-cells, but instead contain a predominance of TH2-like and T regulatory cells (Tregs). In addition, papillomas also are infiltrated with immature Langerhans cells (iLCs). In this study, we show that papilloma cells express IL36γ protein, and that human keratinocytes transduced with HPV11 have reduced IL-36γ secretion. We now provide the first evidence that peripheral blood-derived iLCs respond to IL-36γ by expressing inflammatory cytokines and chemokines. When
stimulated with IL-36γ, iLCs from patients with RRP had lower expression levels of the TH2-like chemokine CCL-20 as compared with
controls. Patients’ iLCs also had decreased steady state levels of CCL-1, which is a proinflammatory chemokine. Moreover, CCL-1
levels in iLCs inversely correlated with the severity of RRP. The combined decrease of TH1- and a TH2-like chemokines by iLCs from
patients could have consequences in the priming of IFN-γ expression by CD8+ T-cells. Taken together, our results suggest that, in
RRP, there is a defect in the proinflammatory innate immune responses made by iLCs in response to IL-36γ. The consequence of
this defect may lead to persistent HPV infection by failing to support an effective HPV-specific, TH1-like and/or Tc1-like adaptive response, thus resulting in the predominant TH2-like and/or Treg micromilieu present in papillomas.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2014.00098

INTRODUCTION
Recurrent respiratory papillomatosis
(RRP) is a disease of the upper airway
characterized by persistent human papillomavirus type 6/11 (HPV 6/11) infection that results in the chronic recurrence
of benign tumors that can cause complete laryngeal occlusion. HPV infection
of the airway is not uncommon, yet RRP

is a rare disease. We have reported previously that patients with RRP have a biased TH2-like and/or Treg, antiinflammatory adaptive immune response to these
HPVs (1–3). To determine the repertoire
of immunologically relevant genes and
pathways that are responsible for this
skewed adaptive response, we previously performed a paired microarray
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analysis using papilloma tissues and
clinically normal laryngeal tissues from
the same patient to identify differential
expression of genes and gene pathways
in the papillomas (4). We observed that
expression of the proinflammatory cytokine IL-36γ was markedly upregulated.
In marked contrast to this observation,
papilloma tissues fail to show signs of inflammation. To explore this paradox, and
better understand why the immune system of RRP patients fails to control persistent laryngeal HPV infection, we have
now addressed the innate immune responses made by Langerhans cells (LCs)
in response to IL-36γ in patients with
RRP.
IL-36γ is a member of the IL-1 superfamily that includes three closely related
genes, IL-36α, β, and γ, formerly known
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as IL-1F6, F8, and F9 respectively. IL36α has been detected in both neuronal
and synovial tissue, whereas IL-36β and
IL-36γ are expressed in both cutaneous
and mucosal epithelial cells, including
the respiratory tract. IL-36β and IL-36γ
stimulate proliferation, maturation
and/or cytokine expression by innate
immune cells (such as keratinocytes and
dendritic cells), and adaptive immune
cells (neutrophils and T-cells) in both
humans (5–8) and mice (9). A genetic
defect in the regulation of IL-36γ stimulation results in the multisystemic inflammatory disease termed generalized
pustular psoriasis (10), illustrating the
importance of proper regulation of the
proinflammatory signaling pathway
mediated by IL-36 ligands in maintaining a normal epithelium (11).
The specific effect of IL-36γ stimulation of LCs, which are the resident professional antigen-presenting cells
within the epithelium of the skin and
mucosa, has not been described previously. Here we provide the first evidence that immature, monocyte-derived
Langerhans cells (iLCs) respond to IL36γ stimulation by increasing the expression of a specific subset of proinflammatory cytokines and chemokines.
Monocyte-derived iLCs from patients
with RRP show impaired upregulation
of inflammatory mediators, especially
CCL-20, following stimulation by IL36γ, coupled with a lower basal expression of CCL-1 that correlates with disease severity. In addition, IL-36γ
stimulation of both laryngeal and foreskin keratinocytes increases the expression of IL-36γ mRNA itself, similar to
that observed for both IL-36β and IL-1β
(12,13) indicating that a positive autocrine feedback loop exists in keratinocytes. However, we also find that
HPVs can interfere with IL-36γ protein
release from infected keratinocytes,
which would further reduce the response by resident iLCs in papilloma
tissues. Taken together, these results
suggest that the normal innate immune
function of LCs in response to IL-36γ is
impaired in RRP.

MATERIALS AND METHODS
Sample Collection and Preparation
Respiratory papilloma tissue and clinically normal adjacent laryngeal biopsies
were obtained during surgery to remove
papillomas. Neonatal foreskin tissues were
obtained following circumcision. Tissues
were either snap frozen or cultured to generate primary cells as described previously
(14). Airway keratinocytes were used at
passage two or three. Foreskin keratinocytes were incubated in dispase at 4°C
overnight, trypsinized and plated as
single cells in keratinocyte culture media
(3:1 DMEM:Ham’s F-12, 10% FetalClone
II [Fisher Scientific, Pittsburgh, PA, USA
{Thermo Fisher Scientific Inc., Waltham,
MA, USA}], 0.4 μg/mL hydrocortisone,
0.1 nmol/L cholera toxin, 5 μg/mL transferrin, 2 nmol/L 3,3′-5-triiodo-L-thyronine,
5 ng/mL epidermal growth factor [EGF],
5 μg/mL insulin, 10 units/mL penicillin
and streptomycin) in the presence of
mitomycin C-treated J2-3T3 feeder layers,
and used no later than passage five.
Whole blood from patients was collected
in heparin-coated tubes at the time of
surgery. The disease severity score for
each patient studied is a composite value
of the rate of regrowth of papilloma mass
divided by the time in days since the previous surgery (15,16). Any score over 0.06
is classified as severe disease. Control
blood was collected from volunteers with
no history of RRP. All patients and controls signed consent forms, and all studies were approved by the Institutional
Review Board, Feinstein Institute for
Medical Research, North Shore-LIJ
Health System, Great Neck, NY, USA.
Western Blot
Pulverized frozen tissues and cultured
cells were extracted in Tris/NP-40/EDTA
(TNE) buffer (0.1 mol/L Tris pH 8.0, 1%
NP-40, 5 mmol/L EDTA) supplemented
with a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN, USA) for
30 min with final protein concentrations
determined as described previously (17).
Proteins (20 μg per lane) were separated
on 8%-16% SDS-PAGE gels, (Bio-Rad,

Hercules, CA, USA) electroblotted onto
Immobilon-FL membranes, (Millipore,
Billerica, MA, USA) and imaged with the
LI-COR Odyssey (LI-COR Biotechnology,
Lincoln, NE, USA).
Lentiviral Transduction and Analysis of
IL-36γ Release
The upstream regulatory region (URR)
and early genes of HPV (nt7178-5963)
were ligated into the lentiviral vector
pSMPUW (Cell Biolabs, San Diego, CA,
USA) to create a lentiviral vector in which
all early genes of HPV11 are expressed
under the control of their endogenous
HPV promoters. Early passage human
foreskin keratinocyte cultures (HFKs) derived from multiple specimens and
pooled, were infected with 90 copies per
cell of the HPV11-lentiviral vector, or with
the empty vector as a control, and cultured for one week. Total RNA was isolated from transduced HFKs with the
Roche High Pure RNA Isolation Kit
(Roche Diagnostics); Q-PCR was performed using primers specific for
HPV11E7 (forward primer nt133–nt157,
reverse primer nt195–nt212, probe
nt161–nt184); and the signal was compared with that for glyceraldehyde 3phosphate dehydrogenase (GAPDH) to
confirm transduction and viral expression. Transduced keratinocytes containing
either HPV11 or empty vector (control),
were treated with poly (I:C) (HMW) (InvivoGen, San Diego, CA, USA) for 96 h,
after which supernatants were analyzed
by IL-36γ enzyme-linked immunosorbent
assay (ELISA) (Human IL-1F9 ELISA kit,
Aviscera Bioscience, Santa Clara, CA,
USA). The percentage of cell death was
determined by trypan-blue staining of
treated cells, and by measurement of lactic dehydrogenase in the supernatant as
per the manufacturer (Cytotoxicity Detection Kit (LDH), Roche Diagnostics).
Isolation, Culture, and Flow Cytometry
Characterization of MonocyteDerived Langerhans Cells
Mononuclear cells were isolated from
peripheral blood using Ficoll-Paque density gradient centrifugation (GE Health-
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Table 1. RT-Q-PCR primers and probes.
Forward primer
TACCTGTCCTGCGTGTTGAA
AAGTTTTACATGCCCAAGAAGG
TGTTCATTTATGGAAGGGATGA
CCCTGTGATCCATTCACCTAA
GCTGGAGTGTCCACAGCATA
TGAGAGGCACTCCAGGAGAC
GATGAGTACAAAAGTCCTGATCC
TTGCTGCTAGCTGGGATGT
GTGGCTTTTCTGGAATGGAA

care, Fairfield, CT, USA). Monocytes
were negatively selected using a commercially available magnetic isolation kit
(Monocyte Isolation Kit II, Miltenyi
Biotec, Bergisch Gladbach, Germany),
which consistently yielded greater than
90% purity. Isolated monocytes were
suspended at 1 × 106/mL in RPMI 1640
media (Gibco/Life Technologies
[Thermo Fisher Scientific Inc.]) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA,
USA), 100 ng/mL granulocytemacrophage colony-stimulating factor
(GMCSF), 20 ng/mL IL-4 and 10 ng/mL
TGFβ1 (R&D Systems, Minneapolis,
MN, USA) (18,19). Monocyte cell suspensions were cultured in 6-well polystyrene trays (Falcon, Fisher Scientific
[Thermo Fisher Scientific Inc.]) and supplemented with fresh medium without
IL-4 on d 1 and d 4. On d 6 or 7, cells
were harvested, stained for viability
(Live/Dead Fixable Aqua Dead Cell
Stain Kit [Invitrogen/Life Technologies
{Thermo Fisher Scientific Inc.}]) and then
surface stained with fluorochromelabeled antibodies CD324 APC (BioLegend, San Diego, CA, USA), CD207 PE
and CD1a PE (Beckman Coulter, Brea,
CA, USA), CD83 APC and CD14 Pacific
Blue, (BD Biosciences, San Jose, CA,
USA). After washings, cells were resuspended in 1% formaldehyde and analyzed on a FACSCanto II. Forward scatter area versus forward scatter height
gating was used to remove cell aggregates. Viable cells with large forward
and side scatter properties were analyzed using FlowJo version 7.2.5
(TreeStar, Ashland, OR, USA). Positive

Reverse primer
TCTAGGGTTTTTAATGGGTTTCT
AAGTGAAAGTTTTTGCTTTGAGCTA
TTCTGCTTTTCTTTACGTTTTCATT
TGCGAGAATCCATCAGAAAAC
GCGATAAGCCCTCCTATCAA
AGGGTCCACACTTGCTGATT
CTGCAGCCACTGGTTCTGT
CTGGAGAAGGGTACCTGCAT
CAACCCCAGCAAGGTTCTT

fluorescence staining was established
using isotype and fluorescence minus
one control.
IL-36γ Stimulation and Analysis of
Monocyte-Derived Immature
Langerhans Cells
The iLCs (2.5 × 106; d 6 or 7) were resuspended in media without cytokines
and stimulated for 4 h at 37°C with
10 ng/mL of recombinant active IL-36γ
(aa 18-169) (R&D Systems), or with the
recombinant inactive full length IL-36γ
(aa 1-169) as a control. Cells were collected by centrifugation, and total RNA
isolated, following DNase1 treatment,
as per manufacturers instructions (Qiagen, Valencia, CA, USA). RNA integrity
(RIN > 7.0) was measured using a Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). For microarray analysis, total RNA (300 ng) was reverse
transcribed and biotin-labeled prior to
hybridization to Human HT-12V4 expression arrays (Illumina, San Diego,
CA, USA) as described previously (4).
Data were processed using BeadStudio
(Illumina), and tab-delimited text files
were uploaded to GeneSifter software
(Geospiza Inc., Seattle, WA, USA) and
comparisons of various experimental
conditions analyzed.
For quantitative reverse transcription
polymerase chain reaction (RT-PCR)
analysis, gene-specific intron-spanning
primers were purchased from Applied
Biosystems/Life Technologies (Thermo
Fisher Scientific Inc.), or designed using
a free bioinformatics program (Table 1)
available on the Fisher website (Fisher
Scientific, [Thermo Fisher Scientific Inc.])
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Probe
AGCTGGAG
CTGGAGGA
TGGGGAAG
TCCTCTCC
CAGCTCCC
TGGTGGAG
CAGCAGGC
TGCTGTCC
UPL-H117

Gene name
IL-1β NM_000576.2
IL-2 ENST00000226730.3
IL-1R1
IL-1RacP
IL-1R6
IL-36γ
IL-6
CCL-1
CCL-20

and RT-Q-PCR performed on an Applied Biosystems 7900 HT (Applied
Biosystems/Life Technologies) using the
appropriate universal probes (Roche) together with the insert iScript One-Step
RT-PCR kit (Bio-Rad). Ten nanograms of
total RNA was reverse transcribed at
50°C for 10 min, followed by a 5 min hot
start at 95°C followed by 40 cycles of
2-step PCR at 95°C for 15 sec and 60°C
for 1 min. Individual RNA samples were
run in duplicate and the average Ct values for the gene of interest compared
with the average Ct values for a housekeeping gene (GAPDH) to calculate
δδCt, where fold change = 2[δδCt].
RESULTS
IL-36γ Protein is Expressed in
Respiratory Papillomas
We demonstrated previously that
IL-36γ mRNA is elevated in respiratory
papillomas and that expression correlated with disease severity (4). We now
have confirmed that IL-36γ protein also
was elevated in papilloma tissues in
comparison to clinically normal (CN)
autologous laryngeal epithelium (Figure 1). Shown are Western blots of two
representative pairs of matched tissue
sets. All papilloma tissues examined
(n = 6) expressed abundant IL-36γ protein, which was not detectable at any
appreciable levels in any of the matched
CN tissues.
HPV-11 Suppresses IL-36γ Release
from Keratinocytes
Since respiratory papillomas express
increased IL-36γ mRNA and protein, we
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Figure 1. IL-36γ protein is overexpressed in
papilloma tissues. Western blot showing IL36γ expression levels in papilloma tissue (P)
and autologous clinically normal laryngeal
tissue (CN) from RRP patients. β-actin (lower
panel) shown as a loading control. Representative of six matched pairs of tissues.

then asked whether HPV infection prevents the release of this proinflammatory cytokine. Others have shown that
high concentrations (2.5–25 μg/mL) of
the synthetic TLR-3 ligand poly (I:C),
which is an analog of double-stranded
RNA, can induce release of IL-36γ from
human foreskin keratinocytes (HFKs)
by inducing cell death (20). We have
found that HFKs can be induced to secrete IL-36γ protein at much lower concentrations of poly (I:C) (0.25–0.75
μg/mL) without any detectable cell
death. The amount of IL-36γ secreted in
response to low dose poly (I:C) was
markedly decreased in cells transduced
by HPV-11, but was not completely
blocked (Figure 2A). This difference in
secretion was not caused by differences
in protein expression, since intracellular
levels of IL-36γ were comparable (Figure 2B).
Respiratory Papillomas Contain
Abundant iLCs
Since papillomas contain IL-36γ protein, and at least some IL-36γ can be released from keratinocytes infected with
HPV-11, we asked whether the lack of
inflammation in papillomas reflected
the absence of LCs in the epithelium.
We used immunohistochemistry to determine whether LCs were present in
papillomas and found that they were
easily identified and abundant in papilloma tissues (Figure 3A). These cells

Figure 2. HPV-11 suppresses release of IL-36γ from keratinocytes. Human foreskin keratinocytes
that had been transduced with either a lentivirus construct expressing all early HPV-11 genes
or the empty vector were treated with poly(I:C) or solvent for 96 h. IL-36γ release was measured by ELISA (A), with results shown as the mean ± SD of three assays, *p < 0.05. Comparable levels of intracellular IL-36γ were confirmed by Western blot (B).

had the morphology of dendritic cells
when visualized at high magnification
(Figure 3B). They expressed both CD1a
(Figure 3C) and langerin (CD207) (Figure 3D) but not the maturation marker
CD83 (Figure 3E). Thus, the numerous
LCs in papillomas are immature (iLCs).
We were able to isolate iLCs from small

papilloma biopsies (Figure 3G), and we
determined that they were approximately half as frequent as the lymphocytes that we have previously characterized in respiratory papillomas
(21,22). The absence of both CD14 and
CD1a expression (Figure 3H) confirmed
that they were indeed resident iLCs,

Figure 3. Papillomas contain abundant iLCs. iLCs were CD1a+ (A,B) and langerin+ (C,D),
but CD83– (E). A positive control (lymphoma) was CD83+ (F). (A–B) Paraffin sections, DAB
stain. (C–D) frozen sections, AEC stain. (E–F) Paraffin sections, immunofluorescence with
DAPI counterstain. (G, H) Flow cytometry of LCs isolated from papilloma biopsies. LCs (G,
lower right) were approximately half as frequent as T-cells (G, upper left). LCs were CD14
negative (H, lower right), confirming that they were not monocytes and that there was no
significant contamination by blood.
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Figure 4. Characterization of LCs generated from peripheral blood monocytes. iLCs were generated from isolated peripheral blood
monocytes by incubating blood monocytes with GMCSF, TGF-β1, and IL-4. After 6 d, they were analyzed by flow cytometry. The cells were
E-cadherin+ and approximately 50% were langerin+ (A), but immature (CD83–) (B). Day 11 iLCs (C) could be induced to mature, as measured by surface expression of CD83 and HLADR, when stimulated with either IL-36γ (D) or LPS (E) for 48 h.

and not simply monocytes from the
blood vessels that permeate respiratory
papillomas.
IL-36γ Induces iLCs to Express
Proinflammatory Cytokines and
Chemokines, but iLCs from Patients
with RRP Show Reduced Responses
Compared with Controls
Because iLCs were present in papillomas, we questioned whether they were
able to respond to IL-36γ. However, nothing was known about the response of
normal iLCs to this cytokine. We therefore first characterized the response of
control iLCs to recombinant IL-36γ, using
monocyte-derived iLCs because they are
abundant and the number of resident
iLCs that can be derived from tissue
biopsies is limited. These blood-derived
iLCs expressed CD1a and E-cadherin on
their cell surfaces, and approximately
half of the cells also expressed langerin
(Figure 4A). The CD1a+ cells were CD83
negative (Figure 4B), consistent with our
finding in papillomas (see Figure 3E) and
reports that characterized resident LCs in
the airway mucosa as immature (23).
Furthermore, they were functional, since
they could be induced to mature when
stimulated with either IL-36γ or
lipopolysaccharide (LPS) (Figures 4C–E).
We initially performed dose response
and time course experiments to determine the optimal conditions for IL-36γ
stimulation. Monocytes on d 2, prior to
differentiation into iLCs, did not respond to IL-36γ but responded to IL-1β

and to lipopolysaccharide (LPS) as expected (data not shown). At d 6, after
differentiation into iLCs, the cells responded to IL-36γ with statistically significant increases in mRNA expression
of both inflammatory cytokines and
chemokines (Figure 5). The response
was detectable at 2–5 ng/mL and maximal at 10–20 ng/mL for all individuals
tested. Comparison of 4, 6 and 8 h exposure to IL-36γ revealed that maximal responses were observed at 4 h and decreased thereafter.
IL-36γ signals through a single heterodimer receptor comprised of IL-1R6
and the receptor accessory protein IL1RacP (IL-1R3). This receptor accessory
protein is common to both the IL-36 receptor and the IL-1 receptor (IL-1R1)
(24). We therefore asked if the expression
of the unique receptor subunit for the

IL-36 receptor changed from d 2 to d 6 of
culture. While IL-1R6 mRNA levels were
four- to eight-fold lower than IL-1R1 and
IL-1RacP, they were still expressed at relatively high levels in the d 2 cells and the
mRNA levels for each of the unique receptor subunits (IL-1R1, IL-1R6), as well
as the common accessory protein IL1RacP, were unchanged between d 2 and
d 6 (Figure 6). This result suggested that
the change in ability to respond to IL-36γ
is not determined by increased expression of either subunit.
Six cultures of iLCs (three from patients with RRP and three controls) were
studied by gene microarray to identify
the broad repertoire of genes that were
upregulated by IL-36γ stimulation.
Among the top 20 genes upregulated at
least three-fold above baseline (Table 2),
seven encoded either cytokines or

Figure 5. Response of iLCs to IL-36γ. Cells were stimulated with either recombinant inactive, full-length (aa 1-169) IL-36γ (control) or the active, shorter form (aa 18-169) of IL-36γ
for 4 h. Induction of mRNA for specific proinflammatory cytokines (A) and chemokines (B)
was measured by q-PCR. Results are the mean ± SD of at least six separate cultures, normalized to control cultures treated with solvent.
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Figure 6. Differentiation of LCs from monocytes does not alter IL-1 receptor and IL-36
receptor expression. Blood-derived monocytes (d 2) and iLCs derived from monoctyes (d 6) were assayed for mRNA expression of IL-1R1, IL-1R3, and IL-1R6 and
compared with GAPDH mRNA expression
(δCT).

chemokines. These genes are shown in
descending order of abundance: CCL-1,
IL-1β, LTα, CCL-20, LTβ, CXCL-1, and
TNF-α. There was no qualitative difference in the transcriptional profiles of iLCs
induced by IL-36γ stimulation between
the patients with RRP and the controls.

We then used qPCR to quantify the enhanced expression of select cytokines
and chemokines using a larger cohort
from controls and patients. As seen in
Figure 7, induction of several proinflammatory mediators was different between
the two groups. iLCs from controls
clearly responded to IL-36γ by markedly
upregulating the expression of the proinflammatory mediators CCL-20, and IL-1β
and TNF-α (see Figure 7), and IL-6 which
can be either pro- or antiinflammatory
(25–28). The response levels varied somewhat between individuals, but they were
increased in all samples. The responses
to IL-36γ were very specific, given that
not all cytokines/chemokines were induced. Expression of IL-2, IL-4, IL-8,
IL-10, IL-12a, and IL-23 were all unchanged (data not shown), as predicted
by the microarray analysis.
The quantitative responses by iLCs
from patients with RRP were reduced
compared with iLCs from controls, with
reduced expression of IL-1β, IL-6, TNF-α

Table 2. Top 20 genes upregulated by IL36γ in iLCs.
Rank
order

p Value

Identifier

1
2

0.00258
7.85e-07

NM_002981
XM_938742

3
4
5
6
7
8
9
10
11
12
13

0.00065
2.15e-06
1.36e-05
3.19e-07
5.76e-06
1.54e-05
0.00166
0.00012
0.00031
2.34e-05
3.39e-05

14
15

0.00035
4.19e-05

16
17

0.00113
0.00027

18
19
20

0.00085
0.00026
0.00041

Gene name/protein name

Chemokine (C-C motif) ligand 1/CCL1
PREDICTED: sphingosine-1-phosphate phosphotase 2
(SGPP2), mRNA.
NM_000930
Plasminogen activator, tissue
NM_007115
Tumor necrosis factor, α-induced protein 6
NM_000576
Interleukin 1, beta/ IL-1β
NM_003327
Tumor necrosis factor receptor superfamily, member 4
NM_153259
Mucolipin 2
NM_001024465 Superoxide dismutase 2, mitochondrial
NM_000595
Lymphotoxin α (TNF superfamily, member 1)
NM_014398
Lysosomal-associated membrane protein 3
NM_004591
Chemokine (C-C motif) ligand 20/CCL20
NM_001024466 Superoxide dismutase 2, mitochondrial
NM_003037
Signaling lymphocytic activation molecule family
member 1
NM_002341
Lymphotoxin β (TNF superfamily, member 3)
NM_003088
Fascin homolog 1, actin-bundling protein
(Strongylocentrotus purpuratus)
NM_172374
Nucleoporin 62kDa
NM_001511
Chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)/CXCL1
NM_001165
Baculoviral IAP repeat-containing 3
NM_178452
Leucine rich repeat containing 50
NM_000594
Tumor necrosis factor (TNF superfamily, member 2)/TNF-α

Figure 7. iLCs from patients are less responsive to IL-36γ. Cells from both healthy controls and RRP patients were stimulated
with active IL-36γ for 4 h, and increased
expression of proinflammatory cytokines
and chemokines measured by q-PCR. A
consistent pattern of blunted expression
by the patient-derived LCs was evident,
with the difference in CCL20 significant
and the difference in IL-1β just missing significance. Results are the mean ± SD of at
least six separate iLC cultures from controls
and seven isolates from patients. *p < 0.05.

and CCL20 (see Figure 7). Of note, the
reduction in CCL-20 was significantly
different (p < 0.05), reduction of IL-1β expression approached significance (p =
0.06), and a trend to reduced expression
was clearly seen for IL-6 and TNF-α. It is
possible that analysis of a larger cohort
of patients would show a significant reduction in the levels for all four immune
mediators.
Constitutive CCL-1 Expression by iLCs
from Patients’ with RRP Correlates with
Disease Severity
CCL-1 was the most elevated immune
mediator following IL-36γ stimulation,
increasing more than 100-fold (p < 0.05)
in controls, but mean levels of induction
did not differ between RRP patients and
controls. However, there was considerable variability in the baseline levels of
CCL-1 expressed by the patients’ cells.
We therefore asked whether there was a
correlation between CCL-1 mRNA levels
in unstimulated iLCs from patients and
the severity of their disease (Figure 8).
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Figure 8. Expression of CCL1 in iLCs correlates with severity of RRP. The level of constitutive CCL1 expression in iLCs from patients with RRP was determined by q-PCR.
Expression levels in iLCs from eight controls
were defined as 100%; and individual samples clustered tightly around the 100%
value (not shown); there was nearly a twolog reduction in expression as severity increased in the patients, p < 0.0001. Disease severity score is a composite value
of the rate of regrowth of papilloma mass
divided by the time in days since the previous surgery. A score over 0.06 is classified
as severe disease.

The highest constitutive expression was
detected in patients with mild disease, at
levels comparable to the controls without
RRP. In contrast, there was significantly
lower baseline expression in patients
with moderate or severe disease, with
the most severe patients having the lowest baseline levels. Thus, low constitutive
CCL-1 mRNA expression by iLCs from
patients predicted disease severity.
DISCUSSION
Infection of laryngeal keratinocytes
with HPV6/11 induces the production of
a number of inflammatory cytokines, including IL-36γ, which should facilitate a
proinflammatory adaptive immune response that ultimately results in the
clearance or control of this infection. The
chronic nature of RRP suggests that, especially for those with severe disease, an
effective adaptive immune response to
these viruses is not achieved. We previously showed that the adaptive immune
responses made by RRP patients are polarized toward immune tolerance of

HPVs, with a strong TH2-like and/or
Treg bias (29–32). However, the innate responses that orchestrate the polarization
of the adaptive immune responses to
these viruses had not yet been characterized, and were the focus of this study.
Airway epithelial cells constitute the
primary antimicrobial defense against
aerosolized pathogens by providing a
physical barrier that is enhanced by the
production of mucus and the expression
of proinflammatory cytokines, chemoattractants, and defensins which we have
previously shown to be upregulated in
RRP (4). We also reported that a single
member of the IL-1 superfamily, the
proinflammatory cytokine IL-36γ, was
markedly and consistently upregulated in
respiratory papillomas, yet there was no
evidence of inflammation in these tissues
(4). Select members of the IL-36 family of
cytokines are expressed by both mouse
and human bronchial epithelial cells
(33,34), and by laryngeal keratinocytes
(4). Unopposed signaling from the IL-36
receptor, secondary to the functional loss
of the IL-36 receptor antagonist (IL-36Ra)
has been shown to lead to the severe dermal inflammatory disease generalized
pustular psoriasis (10), illustrating the
strong proinflammatory effects of unregulated IL-36 signaling in the epidermis.
Although it has been shown previously
that myeloid dendritic cells can respond
to IL-36γ (35), those authors used the full
length, inactive form of the protein, which
precluded an appreciation of how this cytokine triggers a proinflammatory response (9). They also suggested that LC
might respond to IL-36γ, but did not demonstrate this. LCS are a migratory subset
of dendritic cells that specialize in uptake,
transport, processing and presentation of
antigens to T-cells (36–39), and are essential in generating Tregs that induce tolerance in vitro and in vivo (40). LCs mature
during antigen encounter and migrate to
lymph nodes (41) where they present
peptides to T-cells. The balance of proand antiinflammatory cytokines made by
keratinocytes (42–44), with contributions
from LCs themselves, influence LC migration, maturation, and function.
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There is considerable plasticity in LCs
that skews T-helper cell responses, dependent upon the antigen and the cytokine
milieu present during this encounter (45).
LCs can induce TH1 responses but also
can be converted to support TH2 responses when IL-10 is present (41,46–52).
Thus, LCs can function as either pro- or
antiinflammatory (53–57) mediators of
adaptive immunity. Others have reported
that IL-36β, which binds to the same receptor (IL-1R6) as IL-36γ, can increase expression of IL-12p70 and IL-18 by monocyte-derived DCs, and thereby induce
IFN-γ expression by human TH1-like
T-cells(6). They also reported that IL-36γ
can mature these DCs, manifested by increasing their expression of HLA-DR and
CD83 and reducing CD1a (6). We previously showed that both IL-4 and IL-10 (1)
are expressed in papillomas with little if
any IFN-γ, IL-12, or IL-18 (58,59).
CONCLUSION
In this study, we have shown for the
first time that iLCs generated from peripheral blood monocytes respond to IL36γ by upregulation of additional specific proinflammatory cytokine and
chemokine mRNAs, with high levels of
IL-1β and CCL1 mRNA, and moderate
levels of TNF-α, demonstrating that they
clearly could support adaptive TH1-like
T-cell responses (see Figures 5,7). Their
expression of IL-6 and CCL20 showed
that they also could support TH2-like responses, which has recently been suggested to be the principle role of LCs in
the epidermis (60,61). Acquisition of the
ability to respond to IL-36γ required differentiation to iLCs, since monocytes did
not respond. The mechanism of this difference has not been elucidated, although we have ruled out a difference in
IL-36γ receptor mRNA expression (see
Figure 6). We have been unable to measure receptor protein expression or surface localization using commercially
available antibodies. Future studies will
determine whether there are differences
in activation of signal transduction pathway intermediates downstream of the
receptor.
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The cytokine/chemokine responses of
iLCs from patients stimulated with IL36γ were qualitatively similar to controls,
but the responses were generally less robust (see Figure 7). The lower baseline
expression of the proinflammatory
chemokine CCL-1 in iLCs from patients
with the most severe disease could provide significant insight into the mechanism underlying our earlier studies of
the adaptive response in RRP which
showed that the more extreme the
TH2-like/Treg cytokine polarization of
adaptive immune responses made by patients with RRP, the more severe the disease (4,29,31,32,62). CCL-1 links adaptive
and innate immune function by recruiting LC-like dendritic cells and cytotoxic
CD8+ T-cells (63). CCL-1 is required
along with CCL-17 for the IL-12-induced
coupling of dendritic cells and CD8+
T-cells to generate IFN-γ (64). IL-12 expression and the presence of functional
cytotoxic T-cells are both reduced in RRP,
and IFN-γ expression is extremely low,
while CCL-17 is not reduced (1,31), suggesting that deficient IL-12, linked with
disproportional CCL-1/CCL17 expression, would reduced dendritic cell-naïve
CD8+ T-cell priming leading to reduced
IFN-γ production which is characteristic
of adaptive response in RRP (1,32).
We were surprised by the reduced expression of CCL20 by patients’ iLCs in response to IL-36γ, since this chemokine is
important in recruiting Tregs and LCs
into tissues (23,65,66) and both are abundant in papillomas (22). However, newly
recruited LCs are required for CD8+ T-cell
priming to microbial proteins and adjuvants such as poly(I:C) and flagellin, and
for their subsequent expression of IFNγ(23). Thus, reduced expression of CCL20
by iLCs from RRP patients would alter
the balance between resident and newly
recruited LCs. This, in conjunction with
low baseline levels of CCL-1, may explain
the failure of CD8+CD28– T-cells that are
enriched in respiratory papillomas (29) to
support an inflammatory response.
In summary, we demonstrate, for the
first time, that iLCs respond to IL-36 agonists by increasing their expression of

both pro- and antiinflammatory interleukins and chemokines, but that patients
with RRP have a lower level of response.
Our findings also suggest that suppressed IL-36γ release by HPV-infected
keratinocytes, coupled with the systemic
alterations in iLCs, results in suppressed
innate signaling that contribute to the ineffective adaptive immune responses to
HPV by patients with RRP. Further characterization of the response of resident
iLC in respiratory papillomas to IL-36γ
and other cytokines, together with illuminating the mechanism(s) by which HPVs
alter IL-36γ release, should provide critical insight into how these viruses evade
the normal mucosal immune responses
and why patients with RRP are unable to
control their disease.
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